Free Newsletter
Register for our Free Newsletters
Newsletter
Zones
Advanced Composites
LeftNav
Aerospace
LeftNav
Amorphous Metal Structures
LeftNav
Analysis and Simulation
LeftNav
Asbestos and Substitutes
LeftNav
Associations, Research Organisations and Universities
LeftNav
Automation Equipment
LeftNav
Automotive
LeftNav
Biomaterials
LeftNav
Building Materials
LeftNav
Bulk Handling and Storage
LeftNav
CFCs and Substitutes
LeftNav
Company
LeftNav
Components
LeftNav
Consultancy
LeftNav
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Manufacturing Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
 
 
 
News

Researchers are embarking on first-of-its-kind drug study of a treatment that may reverse damaging effects of emphysema

Boston University : 21 April, 2001  (Technical Article)
Boston University School of Medicine researchers are embarking on a first-of-its-kind drug study of a treatment that may reverse the damaging effects of emphysema. The Feasibility of Retinoid Therapy for Emphysema study, is a National Heart, Lung, and Blood Institute funded clinical trial that will test retinoic acid, a vitamin A derivative, in treating emphysema.
Boston University School of Medicine researchers are embarking on a first-of-its-kind drug study of a treatment that may reverse the damaging effects of emphysema. The Feasibility of Retinoid Therapy for Emphysema study, is a National Heart, Lung, and Blood Institute funded clinical trial that will test retinoic acid, a vitamin A derivative, in treating emphysema.

In 1997, NHLBI-funded scientists reported that retinoic acid had reversed emphysema in the lungs of laboratory rats. A workshop of pulmonary experts organized by the NHLBI shortly thereafter agreed that more information about the biologic effects and safety of retinoic acid in emphysema patients was needed before undertaking large-scale clinical trials. The three-year FORTE Study will investigate the biologic effects and safety profile of retinoic acid treatment in patients with emphysema, providing information that may ultimately be used to design large clinical trials to definitively evaluate the effectiveness of retinoic acid in treating emphysema. 'Emphysema is a devastating disease, and treatment options are extremely limited,' said George O'Connor, MD, MS, an associate professor of medicine at BUSM and principal investigator of the study.

'We hope this study will provide us with a new option that will relieve symptoms and improve quality of life for emphysema patients in our community.'

Emphysema is a lung disease that affects millions Americans, most of them longtime smokers over the age of 45. Emphysema and other forms of chronic obstructive pulmonary disease are the fourth leading cause of death in the United States each year and account for more than $2.5 billion in annual health care costs.

The other centers participating in FORTE include: Columbia University, New York City; University of California, Los Angeles; University of California, San Diego; and University of Pittsburgh.
Bookmark and Share
 
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
 
   © 2012 NewMaterials.com
Netgains Logo